Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated